| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
PALO ALTO, Calif.—Agilent Technologies announced it has acquired Boulder, Colo.-based SynPro Corp., which manufactures short nucleic acid molecules for use by the biopharmaceutical industry. It has also hired the existing staff of 22. The acquisition provides Agilent with a value-added opportunity for its existing platforms that support this industry. According to company estimates, the current nucleic acids synthesis market is approximately $700 million, with an estimated growth potential of 10 to 20 percent per year.
 
"Agilent has identified RNA synthesis as an excellent growth opportunity," said John Eaton, Agilent vice president, Corporate Development. "Acquiring SynPro is a strategic move for us. We are gaining first-rate manufacturing capabilities and deep expertise that will open the door for Agilent to an exciting new market."

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue